LLY
911.65
+0.96%â
JNJ
235.8
+0.14%â
ABBV
205.01
+0.38%â
NVS
147.58
+1.16%â
AZN
184.25
+0.48%â
LLY
911.65
+0.96%â
JNJ
235.8
+0.14%â
ABBV
205.01
+0.38%â
NVS
147.58
+1.16%â
AZN
184.25
+0.48%â
LLY
911.65
+0.96%â
JNJ
235.8
+0.14%â
ABBV
205.01
+0.38%â
NVS
147.58
+1.16%â
AZN
184.25
+0.48%â
LLY
911.65
+0.96%â
JNJ
235.8
+0.14%â
ABBV
205.01
+0.38%â
NVS
147.58
+1.16%â
AZN
184.25
+0.48%â
LLY
911.65
+0.96%â
JNJ
235.8
+0.14%â
ABBV
205.01
+0.38%â
NVS
147.58
+1.16%â
AZN
184.25
+0.48%â
24h
Corrente
Minimo
Massimo
Entrata | -1.5M -6M |
|---|---|
Vendite | -291K 201K |
EPS | -1.14 |
Margine di Profitto | -2,971.144 |
Dipendenti | 32 |
EBITDA | -1.7M -3.3M |
Utili prossimi | 26 mar 2026 |
|---|
Capitalizzazione di Mercato | -17M 2.1M |
|---|---|
Apertura precedente | 0 |
Chiusura precedente | 0 |
By Trading Central
Fiducia
Neutral Evidence
0.8417 / 0.8939 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
23 mar 2026, 23:47 UTC
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update
DJ
LeggI
23 mar 2026, 22:55 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
DJ
LeggI
23 mar 2026, 21:51 UTC
Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update
DJ
LeggI
23 mar 2026, 23:59 UTC
Global Equities Roundup: Market Talk
DJ
LeggI
23 mar 2026, 23:59 UTC
Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk
DJ
LeggI
23 mar 2026, 23:50 UTC
Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk
DJ
LeggI
23 mar 2026, 23:37 UTC
Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk
DJ
LeggI
23 mar 2026, 22:42 UTC
Global Equities Roundup: Market Talk
DJ
LeggI
23 mar 2026, 22:42 UTC
Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk
DJ
LeggI
23 mar 2026, 22:40 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18B
DJ
LeggI
23 mar 2026, 22:23 UTC
Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk
DJ
LeggI
23 mar 2026, 22:22 UTC
Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease
DJ
LeggI
23 mar 2026, 22:21 UTC
Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales
DJ
LeggI
23 mar 2026, 22:21 UTC
Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China
DJ
LeggI
23 mar 2026, 22:20 UTC
Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD
DJ
LeggI
23 mar 2026, 22:20 UTC
Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD
DJ
LeggI
23 mar 2026, 22:19 UTC
Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders
DJ
LeggI
23 mar 2026, 22:19 UTC
Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets
DJ
LeggI
23 mar 2026, 22:18 UTC
Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD
DJ
LeggI
23 mar 2026, 22:15 UTC
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD
DJ
LeggI
23 mar 2026, 22:08 UTC
Ebos Needs to Reset Its Gearing Targets -- Market Talk
DJ
LeggI
23 mar 2026, 21:42 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
LeggI
23 mar 2026, 21:42 UTC
RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK
DJ
LeggI
23 mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK
DJ
LeggI
23 mar 2026, 21:10 UTC
Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com
DJ
LeggI
23 mar 2026, 20:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
LeggI
23 mar 2026, 20:50 UTC
Health Care Roundup: Market Talk
DJ
LeggI
23 mar 2026, 20:50 UTC
Basic Materials Roundup: Market Talk
DJ
LeggI
Modifica del prezzo
By TipRanks
Neutrale
1 ratings
0
Acquista
1
Mantieni
0
Vendi
Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Clearside Biomedical Inc - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Neutral Evidence
The bullish and bearish events are balanced.
A termine intermedio
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
A lungo termine
Weak Bearish Evidence
There is one bearish event.
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$